The similarities described above between the breast cancers that arise in patients with BRCA mutations and basal-like cancer have led to the hypothesis that a deficiency in a component of the BRCA pathway plays an important role in basal-like cancers, thus inhibition of PARP1 could also be an important therapeutic strategy. Here, PARP1 is linked to cancer.